PBMC Monolayer Culture for Preserving Cell Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for analyzing cell populations rely on genetically identical cell lines that do not reflect physiologically relevant states, destroying natural cell-cell interactions and membrane integrity, and fail to account for the complex cellular heterogeneity in human health and disease, particularly in hematopoietic cancers.
Innovation Solution
In vitro production of PBMC and bone-marrow cell monolayers that maintain natural-occurring cell-cell interactions and membrane integrity, allowing for the assessment of these interactions and membrane integrity during formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If centrifugation or gravitational forces are applied to separate cell populations, then cell separation efficiency is improved, but natural cell-cell interactions and membrane integrity are destroyed
Solution Approach 1:
The patent uses an intermediary substance (staining reagent or labeling agent) that can penetrate intact membranes to label cells without requiring membrane disruption. This allows cells to be identified and sorted based on their staining characteristics while maintaining natural cell-cell interactions and membrane integrity throughout the separation process.
Solution Approach 2:
The patent replaces mechanical separation methods (centrifugation, gravitational forces) with a staining-based identification system. Cells are labeled through intact membranes using specific stains, then identified and sorted based on their staining patterns without subjecting them to harsh mechanical forces that would disrupt cell interactions or membrane integrity.
2Measurement precision
If cell populations are isolated using conventional methods, then analysis precision is improved, but physiological relevance is lost
Solution Approach 1:
The patent performs preliminary staining of cells while they remain in their native, interacting state within the cell population. This preliminary labeling action occurs before any separation or isolation steps, allowing cells to be identified and subsequently analyzed with high precision while maintaining their physiological context and natural interactions throughout the process.
Solution Approach 2:
The patent changes the parameter being measured from physical separation characteristics to staining-based biochemical markers. By using stains that bind to specific cellular components or markers on intact cells, the method achieves high analysis precision while preserving the physiological state of cells and their natural interactions, as cells are identified by their staining properties rather than being physically separated.
3Stability of the object's composition
If genetically identical cell lines are used for population analysis, then experimental consistency is improved, but cellular heterogeneity is eliminated
Solution Approach 1:
The patent applies local quality staining to individual cells within a heterogeneous population, allowing each cell to be labeled and characterized based on its specific properties. This enables the analysis of cellular heterogeneity at the single-cell level while maintaining the natural diversity of the population, as each cell's unique staining pattern reflects its specific characteristics rather than forcing uniformity across the population.
Data Source
AI summary
The invention relates to peripheral blood mononuclear cell (PBMC) monolayers or bone-marrow cell monolayers and methods for its culture and corresponding uses of said monolayers. The present invention also relates, in some aspects, to screening methods comprising the PBMC monolayer or bone-marrow cell monolayer of the invention for determination of response or lack of response of a disease to a therapeutic agent and/or drug screening methods. In some aspects, the invention further relates to methods for diagnosing a disease or predisposition to a disease in a PBMC donor or bone-marrow cell donor comprising the PBMCs/bone-marrow cells cultured according to the method of the invention and/or to methods for determining whether the disease is likely to respond or is responsive to treatment with a therapeutic agent.